Recent analyst actions around Exelixis (EXEL) have put the stock back on many investors’ watchlists, as firms update ratings and earnings forecasts following its oncology pipeline progress.
See our latest analysis for Exelixis.
That renewed analyst interest sits against a mixed price backdrop, with a 7 day share price return of 9.75% and a 90 day share price return of 7.43% pointing to fading short term momentum. At the same time, the 3 year total shareholder return of 147.21% and 5 year total shareholder return of 83.51% still reflect a strong longer term outcome.
If Exelixis’s oncology focus has your attention, it can be useful to see what else is available in health focused AI and data driven drug development, starting with our 31 healthcare AI stocks.
With analysts lifting earnings forecasts and the shares trading at an estimated 20% discount to some intrinsic value models, plus about 15% below average price targets, you have to ask: is this a buying opportunity, or is future growth already priced in?
Most Popular Narrative: 13.6% Undervalued
Exelixis last closed at $40.74, while the most followed narrative pegs fair value at $47.17. This creates a gap that centers on its oncology earnings power.
The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships. This has the potential to improve operating leverage and net margins over time as the product portfolio scales.
Want to see what kind of revenue profile and profit margins justify that gap, and how much the model leans on pipeline success and buybacks? The full narrative lays out the earnings path, the assumed profitability step up, and the future multiple needed for $47.17 to stack up.
Result: Fair Value of $47.17 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, it is worth keeping in mind that Exelixis still leans heavily on CABOMETYX and faces trial, pricing, and competition risks that could unsettle this upside story.
Find out about the key risks to this Exelixis narrative.
Next Steps
If this mix of upside arguments and risk flags feels finely balanced, it is worth checking the numbers yourself soon and weighing both sides carefully; our breakdown of 4 key rewards and 1 important warning sign can help you frame that view.
Ready to hunt for your next idea?
If Exelixis has sharpened your focus, do not stop here. Put a few minutes into a wider search and you might spot opportunities others are ignoring.
- Target quality at a discount by checking companies our screener flags as 49 high quality undervalued stocks with resilient cash flows and room for re rating.
- Prioritize strength by focusing on businesses in the solid balance sheet and fundamentals stocks screener (40 results) that combine healthier finances with supporting fundamentals.
- Get ahead of the crowd by scanning our screener containing 24 high quality undiscovered gems where strong underlying metrics have not yet attracted broad attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com